Johnson & Johnson (JNJ) Holdings Lessened by Annex Advisory Services LLC

Share on StockTwits

Annex Advisory Services LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 71.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,002 shares of the company’s stock after selling 7,436 shares during the period. Annex Advisory Services LLC’s holdings in Johnson & Johnson were worth $385,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Twin Capital Management Inc. raised its stake in Johnson & Johnson by 9.0% in the third quarter. Twin Capital Management Inc. now owns 278,900 shares of the company’s stock worth $36,260,000 after buying an additional 23,010 shares in the last quarter. Amalgamated Bank raised its stake in Johnson & Johnson by 1.9% in the third quarter. Amalgamated Bank now owns 312,043 shares of the company’s stock worth $40,569,000 after buying an additional 5,712 shares in the last quarter. Zeke Capital Advisors LLC raised its stake in Johnson & Johnson by 98.3% in the third quarter. Zeke Capital Advisors LLC now owns 60,479 shares of the company’s stock worth $7,863,000 after buying an additional 29,978 shares in the last quarter. Investec Asset Management PTY Ltd raised its stake in Johnson & Johnson by 0.3% in the third quarter. Investec Asset Management PTY Ltd now owns 203,753 shares of the company’s stock worth $26,375,000 after buying an additional 518 shares in the last quarter. Finally, Investec Asset Management LTD raised its stake in Johnson & Johnson by 0.6% in the third quarter. Investec Asset Management LTD now owns 5,085,351 shares of the company’s stock worth $661,146,000 after buying an additional 28,526 shares in the last quarter. Hedge funds and other institutional investors own 65.97% of the company’s stock.

NYSE JNJ opened at $122.71 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.25 and a current ratio of 1.58. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.32. The firm has a market capitalization of $325.54 billion, a P/E ratio of 16.81, a PEG ratio of 1.86 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.06. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The firm had revenue of $20.01 billion for the quarter, compared to the consensus estimate of $19.50 billion. During the same period in the prior year, the firm earned $1.83 EPS. The firm’s revenue was up 12.6% on a year-over-year basis. analysts expect that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th were given a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.93%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date was Friday, May 25th. Johnson & Johnson’s dividend payout ratio is presently 49.32%.

A number of equities analysts recently commented on JNJ shares. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $146.00 price objective for the company in a research note on Thursday, April 5th. Vetr downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 price objective for the company. in a research note on Monday, March 26th. ValuEngine downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, May 22nd. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b” rating in a research note on Friday, May 18th. Finally, Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $148.00 to $143.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 10th. Six analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $141.60.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply